Novartis said a Delaware district court established the patent on its heart-failure drug Entresto was invalid, but the company maintained its guidance for 2023 and its mid-term outlook.
Novartis said a Delaware district court established the patent on its heart-failure drug Entresto was invalid, but the company maintained its guidance for 2023 and its mid-term outlook.